The Impact of GLP-1 Drugs on Food and Beverage Demand
The use of GLP-1 drugs, which is already exerting a significant impact on the US food and beverage market, is set to rise sharply around the world in 2026. Semaglutide, the active ingredient in drugs like Ozempic, goes off-patent in much of the world that year. This means that millions of people are going to change how they eat and drink in the coming years, with significant impacts on the food and drink industry.